Gliomatosis cerebri: A consensus summary report from the First International Gliomatosis cerebri Group Meeting, March 26–27, 2015, Paris, France

Greenfield, Jeffrey P.; Heredia, Alicia Castañeda; George, Emilie; Kieran, Mark W.; Madrid, Andrés Morales La

doi:10.1002/pbc.26169

Cited by 21 publications

(26 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5,8 Molecular profiling of DNA methylation and copy number aberrations in 25 human gliomatosis cerebri patients was able to unequivocally assign the cases to known molecularly defined subgroups of nongliomatosis cerebri diffuse gliomas with no evidence for the existence of a distinct gliomatosis cerebri specific molecular subgroup. 7,28 Since gliomatosis cerebri is characterized by the exceptional growth pattern rather than the cell type of the neoplasm, an in vivo diagnosis of gliomatosis cerebri, in contrast to other gliomas, cannot be obtained solely by brain biopsy but requires MRI to evaluate the extent of the lesions and involvement of brain structures. In all dogs examined in this study population, MRI clearly showed that the lesions extended through at least three contiguous cerebral lobes, and therefore fulfilled the criterion used in human medicine for the diagnosis of the entity formerly known as gliomatosis cerebri.…”

Section: Discussionmentioning

confidence: 99%

Magnetic resonance imaging features of canine gliomatosis cerebri

Schweizer

Henke

Oevermann

et al. 2017

Vet Radiology Ultrasound

View full text Add to dashboard Cite

A retrospective, case series study was undertaken to identify magnetic resonance imaging (MRI) characteristics of gliomatosis cerebri in dogs. Fourteen dogs were included by review of histopathological records and contemporaneous MRI. On MRI, all lesions presented as ill-defined, intraaxial lesions within the left and right forebrain hemispheres with involvement of white and gray matter. Lesions presented as hyperintense areas on T2-weighted and FLAIR sequences and as hypointense or isointense areas on T1-weighted images, with mild parenchymal contrast enhancement in three dogs. Signal changes were noted in three to 10 cerebral lobes. Other most commonly affected structures were the thalamus (13), caudate nucleus (13), interthalamic adhesion (11), hypothalamus (11), callosal commissure (10), hippocampus (9), and quadrigeminal plate (8). Abnormalities within the caudal fossa were noted in 10 dogs. Solid tumor portions were identified in five dogs. The histopathological examination demonstrated in all dogs a widespread diffuse infiltration with neoplastic glial cells in white and gray matter with meningeal infiltration. Comparison between MRI and histopathology showed that all areas with signal changes on MRI corresponded to diffuse and dense infiltration with neoplastic cells. The signal intensity on T2-weighted and FLAIR images reflected the density of neoplastic cells. In all dogs, MRI underestimated lesion extent and meningeal infiltration. Involvement of the caudal fossa was not seen on MRI in three dogs. Despite this, MRI allowed identification of lesions extending into at least three cerebral lobes and therefore satisfying the criteria used for diagnosis of diffuse glioma with gliomatosis cerebri growth pattern in humans.

show abstract

Section: Discussionmentioning

confidence: 99%

Magnetic resonance imaging features of canine gliomatosis cerebri

Schweizer

Henke

Oevermann

et al. 2017

Vet Radiology Ultrasound

View full text Add to dashboard Cite

show abstract

“…Tratamentos anti-angiogénicos, como bevacizumab aparentemente não têm eficácia comprovada, o que pode ser explicado devido à reduzida vascularização e ausên-cia de captação de contraste destes tumores. 10 Contudo, recentemente Burger et al, referem que o bevacizumab poderá ser considerado em pacientes com gliomas de padrão maioritariamente infiltrativo.…”

Section: Discussionunclassified

Gliomatose Cerebral: Caso Clínico e Revisão da Literatura

Ramos

Antunes

Machado

et al. 2017

Gaz Med

View full text Add to dashboard Cite

RESUMORelatamos o caso de um doente com diagnóstico de gliomatose cerebral que após dois quadros de hipertensão intracraniana grave, iniciou quimioterapia paliativa e evoluiu de forma clínica e imagiologicamente satisfatória. Doente de 33 anos de idade, previamente autónomo (Karnofsky Performance Status Scale de 100 pontos) e sem antecedentes pessoais/familiares relevantes. É investigado com tomografia computorizada e ressonância magnética cerebral no contexto de crise convulsiva inaugural. É detetada uma lesão infiltrativa fronto-parietal direita com extensão parietal contralateral através do esplénio do corpo caloso. Foi submetido a biópsia lesional por neuronavegação com diagnóstico histológico de astrocitoma grau II (OMS). Perante a integração imagiológica e anatomopatológica define-se então um processo de gliomatose cerebral. Após alta hospitalar recorre por duas vezes ao serviço de urgência com quadro de hipertensão intracraniana grave, uma das quais em estado de coma e com anisocoria pupilar. Após internamento e corticoterapia endovenosa em altas doses, recupera neurologicamente para o seu estado basal. Vinte e sete meses após o diagnóstico, encontra-se assintomático, sem défices neurológicos focais e com estabilidade imagiológica da lesão tumoral. A gliomatose cerebral é uma neoplasia rara, de apresentação clínica variável e com um diagnóstico baseado nas características imagiológicas e histológicas. Após o início dos tratamentos complementares, nomeadamente quimioterapia, poderá ser possível uma estabilização clínica e imagiológica prolongada. PALAVRAS-CHAVE: Neoplasias Cerebrais; Neoplasias Neuroepiteliais ABSTRACTWe report a case of gliomatosis cerebri that after two episodes of severe intracranial hypertension, started palliative chemotherapy and progressed satisfactory clinically and imagiologically. A 33-year-old male patient, previously autonomous GAZETA MÉDICA Nº3 · VOL. 4 · JULHO/SETEMBRO 2017 · 145

show abstract

“…In the revised WHO Classification of Tumors of the Central Nervous System (2016), GC is no longer defined as a single entity and several new entities including “diffuse midline glioma with H3 K27M‐mutant” have been introduced 1 . The term “GC,” however, is still used to describe its characteristic growth pattern 2‐4 . As previously reported, GC is neither pathologically nor genetically grouped into a single entity, but most cases share molecular abnormalities commonly found in other gliomas including hot spot mutations and methylation signatures.…”

Section: Figurementioning

confidence: 99%